GENELUX CORP (GNLX)
US36870H1032 - Common Stock
GENELUX CORP
NASDAQ:GNLX (9/28/2023, 7:00:01 PM)
After market: 24.03 0 (0%)24.03
-0.4 (-1.64%)
Company Profile
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 15 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from solid tumor types. Its advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. The firm is focused on Phase II clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Its Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT) Immunotherapy is an indication-agnostic personalized anti-cancer therapy designed to safely maximize the number and effect of cancer neoantigen-specific effector T cells within cancer tissues. Its animal health product candidate, V-VET1, is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus that is a naturally attenuated isolate.
Company Info
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA
P: 18052679889.0
Employees: 15
Website: https://genelux.com/
GNLX News
14 hours ago - Seeking AlphaGenelux director continues to dispose of stake (NASDAQ:GNLX)Genelux director continues to sell stake in biopharmaceutical company, with a total of 28 sells out of 34 insider trades in the past 3 months.
7 days ago - Seeking AlphaGenelux director disposes of stake (NASDAQ:GNLX)Genelux (GNLX) stock falls as director Szalay Aladar sells off his direct and indirect stake in the company, disposing of 62,459 shares.
15 days ago - Genelux CorporationGenelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today...
21 days ago - Genelux CorporationGenelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceWESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today...
GNLX Twits
Here you can normally see the latest stock twits on GNLX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
